NBTX-001

Nobilis Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	NBTX-001
Sponsor	Nobilis Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Xenon Inhalation for Treatment of Panic Disorder (PHASE2, PHASE3)
Xenon Inhalation for Treatment of Posttraumatic Stress Disorder (PHASE2, PHASE3)
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NBTX-001 CI brief — competitive landscape report
NBTX-001 updates RSS · CI watch RSS
Nobilis Therapeutics Inc. portfolio CI